
Champions Oncology (CSBR) Stock
Biotech firm providing cancer models for drug development. Here's the price, business snapshot, and what's worth knowing about Champions Oncology in November 2026.
Champions Oncology (CSBR) is a small‑cap biotechnology firm (market cap ~ $91.6M) that specialises in oncology-focused preclinical services and precision medicine tools. The company develops and licences patient‑derived tumour models (“tumour avatars” or PDX models) and offers contract research services to pharmaceutical and biotech clients for drug testing, biomarker discovery and preclinical efficacy work. For investors, key attractions include a niche technical offering that can de‑risk drug programmes and partnerships with drug developers. Key risks are typical of early‑stage biotech: revenues can be lumpy, commercial wins may be concentrated, R&D and model validation require ongoing investment, and regulatory or scientific setbacks are possible. The stock can be comparatively volatile and less liquid than larger peers. This summary is educational only and not personal investment advice; investors should consider their risk tolerance, diversification and seek independent financial advice before investing.
Champions Oncology (CSBR) Stock Forecast
Analyst price target, next 12 months
$8.00
+63.3% vs today's $4.90
Price range over the last 12 months
Close to its 12-month low
Analysts covering Champions Oncology have a consensus 12-month target of $8.00, above the current price of $4.90.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Champions Oncology's stock as its target price is slightly above the current price.
Financial Health
Champions Oncology has moderate revenue and cash flow, but its profitability is relatively low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Tumour Avatars Insight
Patient‑derived tumour models can help predict drug responses and support biomarker discovery, though scientific validation and commercial uptake are ongoing.
Partnerships Drive Revenue
Contracts and collaborations with pharma firms are central to growth, but revenues may be irregular and depend on successful client programmes.
Small‑Cap Considerations
With a roughly $92M market cap, expect higher volatility and lower liquidity than larger peers; investors should weigh this alongside potential upside.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.